A Phase II Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Immunogenicity of V212 in Adult Patients With Autoimmune Disease.

Trial Profile

A Phase II Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Immunogenicity of V212 in Adult Patients With Autoimmune Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2017

At a glance

  • Drugs V 212 (Primary)
  • Indications Varicella zoster virus infections
  • Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 01 Oct 2017 Primary endpoint (Immunological response rate) has been met, according to results published in the Clinical Infectious Diseases.
    • 01 Oct 2017 Primary endpoint (Geometric mean antibody titre) has been met, according to results published in the Clinical Infectious Diseases.
    • 01 Oct 2017 Results assessing the immunogenicity and safety of V212 for the prevention varicella zoster virus infections in patients with autoimmune diseas, were published in the Clinical Infectious Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top